Compounded Retatrutide, MariTide, and Investigational Peptides: Why They Are Not Legitimate

A pattern has emerged in the peptide marketplace that needs direct, plain-language documentation: vials labeled with the names of investigational pipeline compounds — retatrutide, MariTide, mazdutide, pemvidutide, petrelintide, others — are being marketed and sold as if they were legitimate prescription products. They are not. Not legally, not regulatorily, not in any sense that aligns with the standard of care or the regulatory framework.

This post explains why, in detail, with the regulatory mechanics laid out so the reasoning is transparent. The goal is not to disparage the compounding industry — TelePeptide prescribes legitimately compounded approved peptides through licensed 503A and 503B partners, and that is a legal and clinically appropriate model. The goal is to draw a clear line between legitimate compounding (which exists and serves real patient needs) and the marketing of investigational compounds outside the regulatory framework (which is something else).

What investigational means

When a compound is described as "investigational" or "in clinical trials," the regulatory state is specific:

1. The compound has an Investigational New Drug (IND) status with the FDA. The sponsor (drug developer) has filed the IND, and the FDA has permitted clinical investigation under specified protocols.
2. The compound is not approved for any indication. It cannot be legally marketed, prescribed, or sold as a medication outside of the trial context.
3. The compound's identity, manufacturing process, and clinical use are restricted to the trial protocol. Manufacturing is done under good manufacturing practice (GMP) standards by or for the sponsor, with strict chain-of-custody controls. Material outside the trial supply chain is not the same compound, even if it has a similar name.

When you see "Phase 3" or "FDA submission expected" in a clinical-trial readout, the compound being studied is the sponsor's specific drug substance, manufactured under specific conditions, supplied through specific channels, and used under specific protocols. That compound is not available outside those channels.

What 503A and 503B compounding actually permit

The FDA's compounding framework, established under the Drug Quality and Security Act (DQSA), defines two pathways:

Section 503A. Patient-specific compounding by state-licensed pharmacies. The compounded preparation is prepared for a specific identified patient on the basis of a valid prescription from a licensed prescriber. The active ingredient must be one of the following:

• A component of an FDA-approved drug, OR
• An ingredient that appears on the United States Pharmacopeia (USP) or National Formulary (NF) monograph, OR
• An ingredient that appears on the FDA's list of bulk drug substances that may be used in compounding under 503A.

Section 503B. Outsourcing facilities that compound non-patient-specific quantities of preparations under FDA registration and oversight. Outsourcing facilities have analogous but distinct lists of permitted bulk drug substances.

The pattern across both pathways is the same: the active ingredient must be on a specific FDA-recognized list. Investigational compounds — by definition, compounds in clinical trials and not yet approved — are not on any of those lists. There is no legal compounding pathway for retatrutide, MariTide, mazdutide, pemvidutide, petrelintide, or any other investigational compound on the late-stage pipeline.

This is not a gray area. Compounding the active ingredient of an investigational drug is not authorized under 503A or 503B. Selling "compounded retatrutide" or "compounded MariTide" is operating outside the regulatory framework that governs legitimate compounding.

Why the shortage pathway does not apply

A common confusion: "Compounded semaglutide and tirzepatide are legal — why are these investigational compounds different?"

The answer is FDA's shortage pathway. When an FDA-approved drug enters the FDA's shortage list, 503A and 503B pharmacies become permitted to compound preparations of the approved drug's active ingredient under specific shortage-related rules. This pathway is what enabled the rise of legally compounded semaglutide and tirzepatide during the 2023-2024 shortage windows.

Two requirements for the shortage pathway:

1. The drug must be FDA-approved. Compounded semaglutide is the same active ingredient as approved branded semaglutide products. The shortage pathway permits compounded preparations of this approved active ingredient.
2. The drug must be on the FDA shortage list. Without active shortage status, the pathway does not apply.

Investigational pipeline compounds fail the first requirement. Retatrutide is not approved. MariTide is not approved. Mazdutide is not approved (in the US). Pemvidutide is not approved. Petrelintide is not approved. None of these compounds have FDA approval, so the shortage pathway is structurally inapplicable to them. Even if FDA were to approve any of them tomorrow, a parallel shortage status would also be required for the compounding pathway to open — and shortage status is determined by post-launch supply, not by approval alone.

What is actually in vials sold as compounded investigational peptides

Without FDA-recognized identity standards, what is in these vials is a research question rather than a regulatory category. The honest range:

Some vials contain the named molecule at uncertain concentration. Some research-grade peptide suppliers do produce peptides matching the published structures of investigational compounds. The molecule may be present, but the concentration, purity, and impurity profile is not held to drug-product standards.

Some vials contain different peptides. Cross-contamination, mislabeling, or substitution can occur in research-grade supply chains. Without analytical testing, the contents are not verified.

Some vials contain contaminants from the synthesis process. Peptide synthesis produces side products, residual solvents, and synthesis byproducts that are removed by GMP purification but may persist in research-grade material.

Some vials contain non-peptide adulterants. Bulking agents, excipients chosen for solubility or appearance, or in worst cases substituted compounds entirely.

The point is not that all research-grade peptide material is dangerous — much of it is what it claims to be, used in legitimate laboratory contexts where chain of custody and identity verification are part of the experimental workflow. The point is that drug-product use requires drug-product standards. Self-administering research-grade material as a substitute for an FDA-approved drug means accepting an identity, potency, and purity profile that is not held to drug standards.

Why the marketing claims are misleading

The marketing surface of vendors selling "compounded retatrutide" or "compounded MariTide" tends to use a few recurring strategies:

Conflating the molecule with the drug product. "Retatrutide" can refer to the chemical entity studied by Eli Lilly. Some research-grade synthesis can produce peptides that match that structure. The marketing claim implies that "retatrutide molecule = retatrutide drug." This is incorrect. The drug product is the molecule plus the formulation, manufacturing, identity verification, sterility assurance, and chain of custody that makes it a drug rather than a chemical sample.

Citing public clinical-trial efficacy data. Vendors point to phase 2 or phase 3 weight-loss readouts as if those numbers apply to their product. They do not. The clinical-trial data was generated using sponsor-manufactured drug product administered under sponsor-defined protocols. Research-grade material at uncertain concentration administered without protocols is not the experiment that generated the data.

Using FDA-approval-related language without claiming approval. "Pharmaceutical grade," "research grade," "lab tested" — these are terms used to suggest legitimacy without making FDA-approval claims that would be obviously false. None of these terms is equivalent to FDA approval.

Operating in regulatory gray areas. Some sources market peptides as "research only, not for human consumption" while structuring sales channels and marketing language to drive personal-use purchase. The disclaimer is not legal protection if the actual sales pattern indicates intended human use.

What this means for patients

For patients considering investigational pipeline compounds, the practical implications:

1. The investigational compounds are not available legitimately in 2026. Retatrutide, MariTide, mazdutide, pemvidutide, petrelintide, others — none can be prescribed, compounded, or legally provided to patients in the US in 2026.
2. Vials marketed as compounded investigational peptides are not the investigational drugs. They are research-grade material with uncertain identity, potency, and purity. The risk profile is meaningfully different from approved drugs or legitimately compounded approved drugs.
3. The legitimate access path is approval, not compounding workarounds. When investigational compounds are approved, they will be available through approved-drug supply chains. Until that happens, the answer is to wait or to use currently approved alternatives.
4. The 12-peptide watchlist remains a watchlist. Track approval status, don't operate as if approval has occurred. The compounds on the late-stage pipeline are real and meaningful; their availability is in the future, not now.

TelePeptide's position

TelePeptide does not, will not, and cannot prescribe compounded versions of investigational pipeline peptides. The reasons:

• It would not be legitimate. No legal compounding pathway covers investigational compounds.
• It would not be safe to recommend. Research-grade material is not held to drug-product standards.
• It would not be consistent with the standard of care. Investigational compounds are prescribed through clinical trials, not through commercial channels.
• It would undermine the model. TelePeptide's prescribing posture is approved drugs through licensed pharmacy channels, with transparent pricing and clinically grounded protocols. Compounded investigational pipeline compounds are outside that model.

When the compounds on the 12-peptide watchlist are approved, we will offer them through the approved-drug supply chain. Until then, the answer to "can I get compounded retatrutide / MariTide / mazdutide" is no — and any source that says otherwise is misrepresenting the regulatory framework.

What patients can legitimately access in 2026

The question after reading the above is reasonably: what can I get?

For approved GLP-1-class therapy in 2026:

• Branded approved products through standard pharmacy channels with prescription.
• Legitimately compounded versions of approved active ingredients (compounded semaglutide, compounded tirzepatide) through licensed 503A or 503B pharmacies during applicable shortage or compounding-eligible windows, prescribed by US-licensed clinicians.

For approved GHRH-class therapy in 2026:

• Sermorelin through licensed 503A compounding pharmacies, prescribed by US-licensed clinicians.
• Tesamorelin as the branded approved product through standard pharmacy channels with prescription.

For NAD+ and other approved peptide therapies in 2026:

• NAD+ injectable preparations through licensed 503A compounding pharmacies, prescribed by US-licensed clinicians.

For investigational pipeline compounds in 2026:

• Clinical trial enrollment is the legitimate access path. Trial registries (clinicaltrials.gov) list active trials for the compounds on the watchlist.
• Watchful waiting until FDA approval is the realistic option for patients who do not enroll in trials.

Bottom line

Investigational pipeline peptides cannot be legitimately compounded under US regulatory law. Vials sold as "compounded retatrutide," "compounded MariTide," or compounded versions of any other pipeline compound are not the investigational drugs. They are research-grade material with uncertain identity, potency, and purity. The legitimate access path is approval, and approval is not 2026 for any compound on the 12-peptide watchlist. Patients tracking the pipeline should base 2026 prescribing on currently approved compounds and revisit when approval occurs.